# Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine

> **NCT01980836** · PHASE4 · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Cellular Immune Response

## Interventions

- **BIOLOGICAL:** Seasonal influenza vaccine

## Key facts

- **NCT ID:** NCT01980836
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-11
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01980836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01980836, "Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01980836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*